NovaBay^® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces its commitment to donate 2.5 million KN95 protective masks to schools, youth groups and other charitable organizations.

“We have been selling masks throughout the pandemic, yet during this critical time with the highly contagious Omicron variant spreading so rapidly, we have decided to donate masks as well,” said Justin Hall, NovaBay CEO. “These protective masks are high quality, having particulate filtration efficiency of 95% or above, and offer better protection than just a cloth mask. Several organizations have already been identified for donations; however, we are still welcoming new requests.”

For qualified 501(c)(3) charitable organizations interested in receiving a donation of KN95 protective masks, please contact Bree Harrison at bharrison@novabay.com. Donations will only be made to charitable organizations and schools. The KN95 protective masks are offered to non-charitable customers in a box of 10 for $9.99 here.

Recently updated Centers for Disease Control and Prevention (CDC) guidelines state that masking is a critical public health tool for preventing the spread of COVID-19. While reminding the public that any mask is better than no mask, the CDC provided guidance that well-fitting N95 or KN95 protective masks offer more protection against COVID-19 spread than loosely woven cloth products. See this blog for a discussion of the differences between N95 and the KN95 masks.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven consumer products for the eyecare and skincare markets. Avenova^® is the nation’s most prescribed antimicrobial lid and lash spray for blepharitis and dry eye. In November 2021, NovaBay acquired DERMAdoctor, LLC, a company offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.

NovaBay Pharmaceuticals Forward-Looking Statements

Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding current product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email sales@avenova.com

Avenova.com

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:

Please call 877-337-6237 or email service@dermadoctor.com

DERMAdoctor.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005398/en/